5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.

      Alzheimer Disease and Associated Disorders
      Aged, Alzheimer Disease, drug therapy, metabolism, physiopathology, Blood Pressure, drug effects, Clinical Trials as Topic, Clonidine, adverse effects, therapeutic use, Female, Heart Rate, Humans, Male, Physostigmine

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Reports of cholinergic and noradrenergic deficits in brain specimens from Alzheimer patients have suggested that concomitant augmentation of cholinergic and noradrenergic neurotransmission can benefit some dementia of the Alzheimer type (DAT) patients. However, pharmacological agents that enhance central cholinergic and noradrenergic neurotransmission, like physostigmine and clonidine, might have serious adverse effects. Therefore, prior to the commitment of major resources in efficacy studies, feasibility pilot studies are necessary to ensure that physostigmine and clonidine, combined, can be safely administered to DAT patients. Physostigmine, 2 mg every 2 h, and clonidine, up to 0.3 mg/day, were tolerated by the nine DAT patients without clinically meaningful adverse effects.

          Related collections

          Author and article information

          Comments

          Comment on this article